Literature DB >> 28341244

Imperatorin suppresses proliferation and angiogenesis of human colon cancer cell by targeting HIF-1α via the mTOR/p70S6K/4E-BP1 and MAPK pathways.

Chunliu Mi1, Juan Ma1, Ke Si Wang1, Hong Xiang Zuo1, Zhe Wang1, Ming Yue Li1, Lian Xun Piao1, Guang Hua Xu1, Xuezheng Li1, Zhe Shan Quan2, Xuejun Jin3.   

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: Angelica dahurica is a commonly used traditional Chinese medicine to treat migraine headache, toothache and cancer. Imperatorin is an active natural furocoumarin component originating from Angelica dahurica and has been shown to exhibit multiple bioeffector functions, including anti-cancer activity. However, the mechanism by which imperatorin inhibits tumor growth is not fully understood. AIM OF THE STUDY: The aim of this study was to investigate the effectiveness of imperatorin as a treatment of cancer and to identify the underlying mechanisms of its anticancer activity.
MATERIALS AND METHODS: HCT116, HeLa, and Hep3B cells were used in this study. Major assays were promoter-reporter gene assay, MTT, western blot analysis, immunofluorescence assay, reverse transcription-PCR (RT-PCR), flow cytometric analysis, clonogenic assay, EdU labeling and immunofluorescence, xenografted assay, and VEGF ELISA.
RESULTS: We here demonstrated the effect of imperatorin on hypoxia-inducible factor-1 (HIF-1) activation. Imperatorin showed a potent inhibitory activity against HIF-1 activation induced by hypoxia in various human cancer cell lines. This compound markedly decreased the hypoxia-induced accumulation of HIF-1α protein dose-dependently, whereas it did not affect the expressions of HIF-1β and topoisomerase-I (Topo-I). Further analysis revealed that imperatorin inhibited HIF-1α protein synthesis, without affecting the expression level of HIF-1α mRNA or degradation of HIF-1α protein. Moreover, the phosphorylation levels of mammalian target of rapamycin (mTOR), ribosomal protein S6 kinase (p70S6K), eIF4E binding protein-1 (4E-BP1), eukaryotic initiation factor 4E (eIF4E), extracellular signal-regulated kinase-1/2 (ERK1/2), SAPK/JNK and p38 were significantly suppressed by imperatorin. Furthermore, imperatorin prevented hypoxia-induced expression of HIF-1 target genes and flow cytometric analysis indicated that imperatorin induced G1 phase arrest in human colon cancer cell (HCT116). We found that imperatorin administration inhibits tumor growth and blocks tumor angiogenesis in a xenograft tumor model.
CONCLUSIONS: These results show that imperatorin inhibited HIF-1α protein synthesis by downregulating the mTOR/p70S6K/4E-BP1 and MAPK pathways. These conclusions suggest that imperatorin is an effective inhibitor of HIF-1 and provide new perspectives into the mechanism of its anticancer activity.
Copyright © 2017 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Antitumor; HIF-1α; Imperatorin; Translation

Mesh:

Substances:

Year:  2017        PMID: 28341244     DOI: 10.1016/j.jep.2017.03.033

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  25 in total

1.  A novel LncRNA HITT forms a regulatory loop with HIF-1α to modulate angiogenesis and tumor growth.

Authors:  Xingwen Wang; Li Li; Kunming Zhao; Qingyu Lin; Huayi Li; Xuting Xue; Wenjie Ge; Hongjuan He; Dong Liu; Hui Xie; Qiong Wu; Ying Hu
Journal:  Cell Death Differ       Date:  2019-11-07       Impact factor: 15.828

Review 2.  Anticancer activities of phytoconstituents and their liposomal targeting strategies against tumor cells and the microenvironment.

Authors:  Jing Zhang; Xiang Li; Leaf Huang
Journal:  Adv Drug Deliv Rev       Date:  2020-05-28       Impact factor: 15.470

Review 3.  Co-Targeting Tumor Angiogenesis and Immunosuppressive Tumor Microenvironment: A Perspective in Ethnopharmacology.

Authors:  Jianbo Zhou; Li Wang; Cheng Peng; Fu Peng
Journal:  Front Pharmacol       Date:  2022-06-15       Impact factor: 5.988

4.  Pharmacological inhibition of sphingolipid synthesis reduces ferroptosis by stimulating the HIF-1 pathway.

Authors:  Yang Liu; Libo He; Binghua Liu; Yuling Ying; Junling Xu; Meng Yu; Jinye Dang; Ke Liu
Journal:  iScience       Date:  2022-06-06

Review 5.  Histone Demethylase JMJD2D: A Novel Player in Colorectal and Hepatocellular Cancers.

Authors:  Qiang Chen; Kesong Peng; Pingli Mo; Chundong Yu
Journal:  Cancers (Basel)       Date:  2022-06-08       Impact factor: 6.575

6.  Targeting Tumor Associated Carbonic Anhydrases IX and XII: Highly Isozyme Selective Coumarin and Psoralen Inhibitors.

Authors:  Claudia Melis; Simona Distinto; Giulia Bianco; Rita Meleddu; Filippo Cottiglia; Benedetta Fois; Domenico Taverna; Rossella Angius; Stefano Alcaro; Francesco Ortuso; Marco Gaspari; Andrea Angeli; Sonia Del Prete; Clemente Capasso; Claudiu T Supuran; Elias Maccioni
Journal:  ACS Med Chem Lett       Date:  2018-06-06       Impact factor: 4.345

7.  Mining genes associated with furanocoumarin biosynthesis in an endangered medicinal plant, Glehnia littoralis.

Authors:  Jiejie Song; Hongmei Luo; Zhichao Xu; Yuxi Zhang; Hua Xin; Dan Zhu; Xunzhi Zhu; Mengmeng Liu; Weiqing Wang; Hongwei Ren; Hongyu Chen; Ting Gao
Journal:  J Genet       Date:  2020       Impact factor: 1.166

8.  Anti-Angiogenic Properties of Ginsenoside Rg3 Epimers: In Vitro Assessment of Single and Combination Treatments.

Authors:  Maryam Nakhjavani; Eric Smith; Kenny Yeo; Helen M Palethorpe; Yoko Tomita; Tim J Price; Amanda R Townsend; Jennifer E Hardingham
Journal:  Cancers (Basel)       Date:  2021-05-06       Impact factor: 6.639

9.  Oleic acid induces apoptosis and autophagy in the treatment of Tongue Squamous cell carcinomas.

Authors:  Lin Jiang; Wei Wang; Qianting He; Yuan Wu; Zhiyuan Lu; Jingjing Sun; Zhonghua Liu; Yisen Shao; Anxun Wang
Journal:  Sci Rep       Date:  2017-09-12       Impact factor: 4.379

10.  Effects of PEP-1-FK506BP on cyst formation in polycystic kidney disease.

Authors:  Hyo Sang Jo; Won Sik Eum; Eun Young Park; Je Young Ko; Do Yeon Kim; Dae Won Kim; Min Jea Shin; Ora Son; Su Bin Cho; Jung Hwan Park; Chi Hern Lee; Eun Ji Yeo; Hyeon Ji Yeo; Yeon Joo Choi; Jong Kyu Youn; Sung-Woo Cho; Jinseu Park; Jong Hoon Park; Soo Young Choi
Journal:  BMB Rep       Date:  2017-09       Impact factor: 4.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.